Kamada Plasma, a 2021 subsidiary, specializes in collecting rare donors’ plasma for KamRho-D, a life-saving medicine manufactured and distributed by Kamada.
Kamada’s growth stems from its employees’ vision, skills, and dedication, including becoming the first Israeli company to gain FDA approval for a biological drug.
Amir London became Kamada’s CEO in July 2015 after serving as Senior Vice President of Business Development. He brings over 20 years of senior management and international business experience.
Kamada partners with industry collaborators to combine strengths and create a greater whole. Its strategic collaborations include an exclusive agreement with Takeda for manufacturing, marketing, and distributing Glassia in the United States and Canada.
The purpose of the Code of Ethics is to put into force within the organization written and binding moral principles and values as a guide for specific behavioral rules that are compulsory for the managers and employees of the company at every level, and to act according to them.
Kamada is a vertically integrated biopharmaceutical company focused on plasma-derived therapeutics, with marketed products, a development pipeline, and industry-leading manufacturing.
